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Objective: To test the hypothesis that changes in the subchondral bone induced by parathyroid hormone
(PTH [1-34]) reciprocally affect the integrity of the articular cartilage within a naïve osteochondral unit
in vivo.
Design: Daily subcutaneous injections of 10 mg PTH [1-34]/kg were given to adult rabbits for 6 weeks,
controls received saline. Blood samples were continuously collected to monitor renal function. The
subchondral bone plate and subarticular spongiosa of the femoral heads were separately assessed by
micro-computed tomography. Articular cartilage was evaluated by macroscopic and histological osteo-
arthritis scoring, polarized light microscopy, and immunohistochemical determination of type-I, type-II,
type-X collagen contents, PTH [1-34] receptor and caspase-3 expression. Absolute and relative extents of
hyaline and calciﬁed articular cartilage layers were measured histomorphometrically. The correlation
between PTH-induced changes in subchondral bone and articular cartilage was determined.
Results: PTH [1-34] enhanced volume, mineral density, and trabecular thickness within the subarticular
spongiosa, and increased thickness of the calciﬁed cartilage layer (all P < 0.05). Moreover, PTH [1-34] led
to cartilage surface irregularities and reduced matrix staining (both P < 0.03). These early osteoarthritic
changes correlated with and were ascribed to the increased thickness of the calciﬁed cartilage layer
(P ¼ 0.026) and enhanced mineral density of the subarticular spongiosa (P ¼ 0.001).
Conclusions: Modiﬁcations of the subarticular spongiosa by PTH [1-34] cause broadening of the calciﬁed
cartilage layer, resulting in osteoarthritic cartilage degeneration. These ﬁndings identify a mechanism by
which PTH-induced alterations of the normal subchondral bone microarchitecture may provoke early
osteoarthritis.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The osteochondral unit is the anatomical regionwhere articular
cartilage and subchondral bone actively and closely interact1. It is
an area of signiﬁcant importance for the maintenance of a physi-
ological joint function but also for pathological changes such as
osteoarthritis2. Although it is well known that both the articular
cartilage and the subchondral bone play a crucial role in theto: H. Madry, Center of





ternational. Published by Elsevier Lpathogenesis of osteoarthritis3e5, little is known about the mech-
anisms of their interaction in the onset of early osteoarthritis6,7.
Parathyroid hormone (PTH) primarily affects the osseous tissue,
is anabolic for osteocytes8, and associated endocrinological disor-
ders such as hyperparathyroidism or pseudo-hyperparathyroidism
may induce hypercalcemia. Its 1-34 amino acid segment (PTH [1-
34])9 is clinically approved for the systemic treatment of post-
menopausal osteoporosis10. Using PTH as a therapeutic agent, the
close interaction of both components of the osteochondral unit11
has been highlighted in models of osteoarthritic cartilage degen-
eration12e14 or focal cartilage defects15,16.
Based on these well-known effects on bone, we aimed to use
PTH [1-34] as a molecule to investigate whether subchondral bone
changes affect the articular cartilage in a naïve osteochondral unit
in vivo, allowing for a better insight in the onset of earlytd. All rights reserved.
Fig. 1. Macroscopic and histological aspect of the articular cartilage in the weightbearing area of lapine femoral heads. According to the scoring system of Wachsmuth et al.19,
systemic administration of PTH [1-34] did not affect the macroscopic aspect of the femoral heads (A). However, the histological scoring system of Laverty et al.21 revealed that the
treatment signiﬁcantly increased the overall severity of degenerative changes within the articular cartilage in vivo (B), mainly due to a decrease in matrix staining intensity and
surface irregularities. Scale bars: 7.0 mm (A), 1.0 mm (B).
P. Orth et al. / Osteoarthritis and Cartilage 22 (2014) 813e821814osteoarthritis. We therefore tested the hypothesis that systemic
treatment with PTH [1-34] induces changes in the subchondral
bone that affect the calciﬁed cartilage and the integrity of the
articular cartilage in the rabbit femoral head. Moreover, we hy-
pothesized that a correlation between key changes in the sub-
chondral bone and the articular cartilage exists.
Materials and methods
Study design
The treatment group (PTH group) received daily injections of PTH
[1-34] for 6 weeks, control animals were daily injected with saline.
Blood samples were collected at days 0, 21, and 42, and animals were
sacriﬁced after 6 weeks. The subchondral bone was assessed by
micro-computed tomography (micro-CT) and immunohistochemical
analyses; hyaline and calciﬁed articular cartilage was evaluated by
macroscopic, histological, immunohistochemical and histomorpho-
metrical assessment. The strength of association between changes in
articular cartilage and subchondral bone was determined.
Animal experiments
All animal procedureswere approved by the local Governmental
Animal Care Committee. Female Chinchilla bastard rabbits were in
their late juvenile stage (n ¼ 8; Charles River, Sulzfeld, Germany;
mean BW: 3.1 kg (3.0, 3.2); mean age: 14 weeks (12, 16)) and
randomly divided into two groups: the treatment group (PTH
group; n¼ 4) received once daily (18:00 h) subcutaneous injections
of 10 mg/kg body weight (BW) of human PTH [1-34] (Bachem,
Bubendorf, Switzerland) dissolved in 0.5 M saline with 2% heat
inactivated bovine serum (BS) over 42 days. Control animals (n¼ 4)
were daily injected with 0.5 M saline with 2% heat inactivated BS
only. The animals were allowed full weight bearing and were fed a
standard diet over the entire observation period.
After 6 weeks, the rabbits were euthanized with pentobarbital
(150 mg/kg BW; Merial, Hallbergmoos, Germany) and hip joints
were entered using a lateral surgical approach. Following transec-
tion of the ligamentum capitis femoris, the joints were luxated andthe proximal femurs were osteotomized at the medial femoral
neck. The explanted femoral heads were photo documented for
macroscopic assessment under standardized illumination condi-
tions17 [Fig. 1]. The animals used here simultaneously served to
assess the effect of PTH [1-34] on osteochondral repair in the knee
joint16.
Micro-CT analysis of the subchondral bone
All femoral heads (n ¼ 8 per group) were scanned (Skyscan 1172,
Skyscan, Kontich, Belgium) in 70% ethanol at a spatial resolution of
13 mm(tube voltage: 70 kV; current: 140 mA; intervals: 0.4; exposure
time: 2,400 ms; ﬁlter: 0.5 mm aluminium/copper). Projections
(1,000e1,200 per specimen) were obtained at interposed. Frontal
sections [Fig. 2] were reconstructed by a modiﬁed Feldkamp cone-
beam algorithm18 (NRecon, Skyscan). Thresholding levels of gray
values (range89e255)were set for segmentationof binary images. To
express gray values asmineral content (bonemineral density; BMD),
calcium hydroxyapatite (CaHA) phantom rods with known BMD
values (250 and 750 mg CaHA/cm3) were employed for calibration.
For the separate assessment of the subchondral bone plate and
the subarticular spongiosa, two individual volumes of interest
(VOIs) were deﬁned. BMD, bone volume fraction (BV/TV), bone
surface/volume ratio (BS/BV), and bone surface density (BS/TV)
were computed in a 3-dimensional fashion in all VOIs (CTAnalyzer,
Skyscan). Cortical thickness (Ct.Th) was evaluated only within the
subchondral bone plate, while trabecular thickness (Tb.Th),
trabecular separation (Tb.Sp), trabecular pattern factor (Tb.Pf),
trabecular number (Tb.N), structure model index (SMI), degree of
anisotropy (DA), and fractal dimension (FD) were assessed in the
subarticular spongiosa18.
Macroscopic assessment of the articular cartilage
Based on the photographs taken immediately after sacriﬁce, the
articular cartilage covering the femoral heads (n ¼ 16) in the
weightbearing area was examined macroscopically in a blinded
fashion. Grading was performed applying an inverse scoring sys-
tem19 (0: normal, 1: focal surface roughness, 2: widespread surface
Fig. 2. Histomorphometrical analysis of the osteochondral unit. Standardized histomorphometrical measuring on Goldner’s trichrome stained histological sections (A) revealed that
the layer of calciﬁed cartilage signiﬁcantly broadened under systemic treatment with PTH [1-34] in vivo. As the mean thickness of the overlying hyaline articular cartilage layer
remained constant, the ratio of calciﬁed cartilage/hyaline cartilage also increased following systemic PTH [1-34] administration (A). Micro-CT analysis revealed a signiﬁcant increase
in BMD, BV/TV and Tb.Th within the subarticular spongiosa of the treatment group. (B). PTH [1-34] did neither affect the number of chondrocytes in the articular cartilage nor the
number of osteocytes within the subchondral bone compartment (C). Scale bars: 0.5 mm (A, C), 7.0 mm (B).
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ﬁbrillation, 5: beginning erosion, 6: severe erosion, 7: slight ulcer-
ation, 8: severe ulceration).
Histological and histomorphometrical analysis of the articular
cartilage
Femoral heads were trimmed, decalciﬁed, and parafﬁn-
embedded frontal sections (5 mm) were stained with safranin or-
ange/fast green (safranin O), haematoxylin/eosin (HE), or Goldner’s
trichrome staining according to routine protocols20. All histological
scoring and histomorphometrical evaluation was performed blin-
ded with regard to the treatment group. Photomicrographs were
obtained using a solid-state CCD camera mounted on a BX-45 mi-
croscope (Olympus, Hamburg, Germany).
For the quantitative assessment of articular cartilage degener-
ation in the weightbearing area of the femoral heads, serial histo-
logical sections were taken at 200 mm intervals. Safranin O-stained
sections [Fig. 1] were analyzed using the inverse grading system
according to Laverty et al.21. A total of 64 sections were scored twice
by one blinded investigator.
The absolute and relative extent of the calciﬁed cartilage layer
wasmeasured histomorphometrically: Goldner’s trichrome stained
histological sections (n¼ 2 per femoral head) were takenwithin the
weightbearing area of the femoral heads at 100-fold magniﬁcation
and digitalized (analySIS docu 5.0, Olympus Soft Imaging Solutions)
[Fig. 2]. At three equidistant points, the thickness of the normal
hyaline articular cartilage and the calciﬁed cartilage was measured.
From these three values per specimen, the mean extent of the
calciﬁed cartilage layer (mm) as well as the mean ratio of calciﬁed
cartilage/hyaline cartilage (%) was determined.
Total cell numbers within the articular cartilage (and the sub-
chondral bone) of the weightbearing area were determined histo-
morphometrically.HE-stainedhistological sections (n¼2per femoral
head) taken at 100-fold magniﬁcation [Fig. 2] were digitalized and
standardized regions of interest (ROIs; height 0.2mm;width 1.0mm;
area 0.2 mm2) were deﬁned (analySIS docu 5.0).Immunohistochemical analysis of the osteochondral unit
Immunostaining was performed as previously described22 using
a 1/50 dilution of a monoclonal mouse anti-type-I, anti-type-II, or
anti-type-X collagen IgG (all Acris, Hiddenhausen, Germany), a
cleaved caspase-3 polyclonal antibody (Asp175; Cell Signaling
Technology, Frankfurt, Germany), or a monoclonal mouse PTH1R
antibody (ab3271; Abcam, Cambridge, UK), and a secondary bio-
tinylated anti-mouse antibody (Vector Laboratories, Grünberg,
Germany).
For the determination of collagen contents within the osteo-
chondral unit, immunohistochemically stained sections [Fig. 3]
were digitalized in a standardized fashion (magniﬁcation 40-fold,
constant light intensity, exposure time, and white balancing).
Immunoreactivity to type-I and type-X collagen in the subchondral
bone as well as immunoreactivity to type-II and type-X collagen in
the articular cartilage was quantiﬁed by computerized assessment
of mean staining intensities (no units; analySIS docu 5.0). Addi-
tionally, visualization of the collagen network (birefringence,
orientation, and anisotropy) within the repair tissuewas performed
using polarized light microscopy.
For the evaluation of apoptosis (caspase-3) and PTH-receptor 1
(PTH1R) expression, standardized images of histological sections
taken at 200-fold magniﬁcation were digitalized. Identical ROIs
(height 300 mm; width 400 mm; area 0.12 mm2) were deﬁnedwithin
the articular cartilage and the subchondral bone compartment, total
cell numbers were extrapolated per mm2, and apoptosis as well as
PTH1R expression rates were determined (analySIS docu 5.0).
Serological analysis
To evaluate a possible renal insufﬁciency due to the treatment
with PTH [1-34], whole blood samples were collected at days 0, 21,
and 42 (08:00 h) from all animals and analyzed for serum levels of
creatinine, phosphate, and urea nitrogen,measured by computerized
multichannel serum analysis. Serum levels of calcium and alkaline
phosphatase were previously reported for these animals16.
Fig. 3. Collagen distribution within the osteochondral unit. Immunoreactivity to type-I collagen within the subchondral bone (A) as well as to type-II collagen in the articular
cartilage (B) was quantiﬁed by computerized assessment of mean staining intensities. No signiﬁcant differences were detected between the PTH and control group. Polarized light
microscopic assessment (C) revealed that collagen ﬁbrils yielded a normal articular cartilage organization in both groups and birefringence of subchondral bone and articular
cartilage was unaffected by PTH [1-34]. Scale bars: 1.0 mm.
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Each test condition was performed with n ¼ 4 independent
animals (n ¼ 8 femoral heads) per group. Since the data involve
multiple observations on different joints from the same animals,Fig. 4. Serological parameters of renal failure under systemic treatment with PTH [1-
34]. Serum concentrations of creatinine, phosphate and urea nitrogen obtained from
whole blood samples at days 0, 21, and 42 of PTH [1-34] administration were similar
between treatment and control group for all time points. For all parameters, serum
concentrations did not differ signiﬁcantly between days 0, 21, and 42 in vivo.these are likely positively correlated when compared to observa-
tions from a different animal. In order to obtain mean comparisons
in the context of a model that takes into account these correlations,
we employed a linear model using generalized estimating equa-
tions with an exchangeable working correlation structure. Based on
given sample sizes and differences in micro-CT parameters of
subchondral bone, a power of 80% for detecting large treatment
effects (approximately 1.5 standard deviations) was achieved with
a ﬁxed, two-sided signiﬁcance level of 0.05. The BlandeAltman
method for calculating weighted correlation coefﬁcients (r) be-
tween subjects with repeated observations23 was used to deter-
mine the strength of association between the thickness of the
calciﬁed cartilage layer, key micro-CT parameters of the sub-
articular spongiosa (BMD, BV/TV, Tb.Th), and the histological pa-
rameters of articular cartilage matrix staining and average total
score. Data are presented as mean values, 95% conﬁdence intervals
are used to denote statistical uncertainty of estimates. Two-tailed
values of P < 0.05 were considered signiﬁcant. Statistical analyses
were performed using the SPSS software package (version 19.0,
SPSS Inc./IBM, Chicago, IL).Results
Systemic responses to PTH [1-34]
Serum levels of creatinine, phosphate, and urea nitrogen
remained unchanged between PTH-treated animals and untreated
controls for all time points (all P  0.063) [Fig. 4, Table I]. In both,
the PTH group and the control group serum concentrations of
creatinine, phosphate, and urea nitrogen were similar between
days 0, 21, and 42 of PTH [1-34] administration (all P  0.051)
[Fig. 4, Table I].
Table I
Serum concentrations of creatinine, phosphate and urea nitrogen displaying renal function at days 0, 21, and 42 of systemic PTH [1-34] administration
Parameter Day 0 Day 21 Day 42
PTH [1-34] Control P PTH [1-34] Control P PTH [1-34] Control P
Creatinine 1.02 (0.95, 1.09) 1.17 (0.87, 1.47) 0.382 0.90 (0.69, 1.10) 0.81 (0.71, 0.91) 0.542 0.91 (0.85, 0.96) 0.88 (0.79, 0.97) 0.644
Phosphate 4.98 (4.19, 5.76) 5.39 (4.45, 6.63) 0.533 4.61 (4.34, 4.87) 5.34 (5.07, 5.61) 0.063 4.38 (4.13, 4.63) 4.56 (3.82, 5.29) 0.672
Urea nitrogen 25.73 (20.42, 31.03) 23.08 (21.54, 24.61) 0.380 30.75 (19.09, 42.41) 38.95 (29.05, 48.85) 0.402 23.63 (18.48, 28.77) 25.48 (18.63, 32.32) 0.691
Serum levels of creatinine, phosphate, and urea nitrogen remained unchanged between PTH-treated animals and untreated controls for all time points (all P 0.063) andwere
similar between days 0, 21, and 42 within both, the PTH-group and the control group (all P  0.051).
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Volume, mineral density and microarchitecture
The BMD (1,062.48 (985.32, 1,139.65) vs 931.59 (886.44, 976.73)
mg CaHA/cm3; P ¼ 0.017) and BV/TV (45.58 (43.02, 48.14) vs 40.12
(37.64, 42.59) %; P ¼ 0.010) were enhanced in the subarticular
spongiosa of PTH-treated animals [Fig. 2]. In good agreement, the
thickness (0.14 (0.13, 0.14) vs 0.13 (0.13, 0.14) mm; P ¼ 0.042) and
number (3.33 (3.17, 3.49) vs 3.05 (2.88, 3.23); P ¼ 0.036) of
trabeculae was also increased in the PTH group, vis-à-vis a decrease
in trabecular separation (0.23 (0.21, 0.24) vs 0.26 (0.25, 0.28) mm;
P ¼ 0.004) (Table II).
No such effect of PTH [1-34] was noted in the subchondral
bone plate: The treatment did not affect volume (96.50 (95.74,
97.25) vs 97.51 (96.70, 98.32) %; P ¼ 0.096), mineral density
(1,148.17 (1,052.11, 1,244.22) vs 1,150.27 (1,084.42, 1,216.11) mg
CaHA/cm3; P ¼ 0.972), or thickness (0.20 (0.18, 0.22) vs 0.20 (0.17,
0.23) mm; P ¼ 0.823) of the cortical subchondral bone plate
(Table II).
In control animals, the subchondral bone plate exhibited a
signiﬁcantly higher BMD than the subarticular spongiosa (1,150.27
(1,084.42, 1,216.11) vs 931.59 (886.44, 976.73) mg CaHA/cm3;
P < 0.001). Interestingly, PTH [1-34] enhanced BMD mainly within
the subarticular spongiosa, resulting in equal values in both regions
of the subchondral bone (1,148.17 (1,052.11, 1,244.22) vs 1,062.48
(985.32, 1,139.65); P ¼ 0.131).Collagen distribution
Immunoreactivity to type-I collagen was similar in the sub-
chondral bone of PTH-treated and untreated animals (mean
staining intensity 142 (131, 153) vs 148 (136, 160); P ¼ 0.501)
[Fig. 3]. Likewise, the immunoreactivity of the subchondral bone to
type-X collagen was also unaffected by PTH [1-34] (166 (160, 172)
vs 163 (155, 171); P¼ 0.587). Birefringence of the subchondral bone
was similar between both groups [Fig. 3].Table II
Micro-computed tomography parameters determined in different VOIs within the subch
Parameter Unit Subchondral bone plate
PTH [1-34] Control
BMD mg/cm3 1,148.17 (1,052.11, 1,244.22) 1,150.27 (1,084.42, 1,216.1
BV/TV % 96.50 (95.74, 97.25) 97.51 (96.70, 98.32)
BS/BV mm1 14.94 (12.96, 16.92) 14.75 (12.59, 16.90)
BS/TV mm1 14.25 (12.49, 16.01) 14.44 (12.34, 16.55)
Ct.Th mm 0.20 (0.18, 0.21) 0.20 (0.17, 0.23)
Tb.Th mm n.a. n.a.
Tb.Sp mm n.a. n.a.
Tb.N mm1 n.a. n.a.
Tb.Pf mm1 n.a. n.a.
SMI / n.a. n.a.
DA / n.a. n.a.
FD / n.a. n.a.
n.a.: not applicable (parameters for trabecular subarticular spongiosa not suitable for coOsteocyte numbers and apoptosis rates
The number of osteocytes within the subchondral bone
remained unchanged by PTH [1-34] (PTH group 884 (667, 1,001);
control group 1,086 (862, 1,300) cells/mm2; P ¼ 0.106). Caspase-3
immunoreactivity revealed generally low apoptosis rates of osteo-
cytes within the subchondral bone (PTH group: 3 (1, 5) %; control
group: 2 (0, 5) %; P ¼ 0.531).
PTH1R expression
Following systemic administration of PTH [1-34], 9 (6, 12) % of
osteocytes within the weightbearing area of the subchondral bone
stained positive for PTH1R. In controls, 10 (6, 14) % exhibited PTH1R
expression. No signiﬁcant difference existed between groups
(P ¼ 0.398).
Effect of PTH [1-34] on the articular cartilage
Macroscopic appearance
Analysis of the macroscopic aspect of the articular cartilage
surface revealed little degenerative changes in both groups (PTH
group 0.75 (0.00, 1.71); control group 0.57 (0.01, 1.13); P ¼ 0.762),
corresponding to mostly normal cartilage with focal areas of sur-
face roughness19 [Fig. 1].
Histological characteristics
Systemic PTH [1-34] application led to a signiﬁcantly impaired
safranin O staining (1.6-fold; 2.75 (1.73, 3.77) vs 1.68 (1.37, 1.99);
P ¼ 0.029) and histological structure (4.4-fold; 1.11 (0.61, 1.62) vs
0.25 (0.00, 0.58); P < 0.001) of the articular cartilage after 6 weeks
in vivo. These score values were reﬂective of a loss of staining in the
upper two thirds of the hyaline cartilage (in less than 50% of the
joint surface) and of surface irregularities21. Treatment with PTH [1-
34] also increased cluster formation 4.5-fold (0.18 (0.00, 0.46) vs
0.04 (0.00, 0.27)), without reaching statistical signiﬁcance
(P ¼ 0.089). Cellularity was not affected by the treatment (0.00ondral bone of lapine femoral heads
Subarticular spongiosa
P PTH [1-34] Control P
1) 0.972 1,062.48 (985.32, 1,139.65) 931.59 (886.44, 976.73) 0.017
0.096 45.58 (43.02, 48.14) 40.12 (37.64, 42.59) 0.010
0.901 24.03 (22.47, 25.60) 25.34 (24.03, 26.66) 0.231
0.895 10.90 (10.47, 11.32) 10.13 (9.65, 10.61) 0.036
0.823 n.a. n.a.
0.14 (0.13, 0.14) 0.13 (0.13, 0.14) 0.042
0.23 (0.21, 0.24) 0.26 (0.25, 0.28) 0.004
3.33 (3.17, 3.49) 3.05 (2.88, 3.23) 0.036
2.23 (-3.37, 1.09) 1.28 (-2.50, 0.07) 0.287
0.34 (0.14, 0.54) 0.43 (0.24, 0.62) 0.533
0.17 (0.15, 0.19) 0.16 (0.12, 0.20) 0.645
2.20 (2.18, 2.22) 2.20 (2.19, 2.22) 0.728
rtical subchondral bone plate and vice versa).
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osteoarthritis score was signiﬁcantly worse (2.2-fold) following
administration of PTH [1-34] (4.28 (3.32, 5.24) vs 1.97 (1.64, 3.30);
P ¼ 0.040) [Fig. 1].
Thickness of the calciﬁed cartilage layer
The calciﬁed cartilage layer broadened 1.7-fold under systemic
treatment with PTH [1-34] (285 (248, 322) vs 163 (140, 186) mm;
P ¼ 0.001) [Fig. 2]. Of note, the mean thickness of the overlying
hyaline articular cartilage layer remained unchanged (447 (428,
466) mm vs 438 (419, 457) mm; P ¼ 0.894). The combined thickness
of hyaline plus calciﬁed cartilage was 1.2-fold increased by PTH [1-
34] (732 (630, 834) vs 601 (516, 686) mm; P ¼ 0.042). Likewise, the
ratio of calciﬁed cartilage to hyaline cartilage was of 65.6 (56.4,
74.8) % in the PTH group, signiﬁcantly higher than in controls (37.7
(33.3, 42.1) %; P ¼ 0.015).
Collagen distribution
Mean staining intensities for type-II collagen in the articular
cartilage were similar in both groups (148 (142, 154) vs 142 (125,
159); P ¼ 0.525) [Fig. 3]. Accordingly, immunoreactivity for type-X
collagen was not inﬂuenced by PTH [1-34] (213 (211, 215) vs 210
(204, 216); P ¼ 0.393). Polarized light microscopic assessment
revealed similar birefringence and organization of collagen ﬁbrils in
both groups [Fig. 3].
Chondrocyte numbers and apoptosis rates
The number of chondrocytes within the articular cartilage
[Fig. 2] was comparable between both groups (PTH group 1,708
(1,523, 1,893); control group 1,669 (1,487, 1,851) cells/mm2;
P ¼ 0.775). Apoptosis rates of chondrocytes were low (PTH group 1
(0, 2) %; control group 1 (0, 2) %; P ¼ 0.774). For both groups, no
signiﬁcant differences were found between apoptosis rates of
chondrocytes and osteocytes (both P  0.133).
PTH1R expression
Within the articular cartilage compartment, the percentage of
chondrocytes that stained positive for PTH1R was low, irrespective
whether the animals were exposed to PTH [1-34] or not (2 (1, 3) %
vs 3 (1, 5) %, respectively; P ¼ 0.336).
Correlation between articular cartilage and subchondral bone
changes
The internal correlation within the articular cartilage between
histological matrix staining and total score value was high
(r ¼ 0.846; P < 0.001). Likewise, internal correlations for micro-CT
parameters of the subarticular spongiosa were high (r ¼ 0.511 for
BMD and BV/TV; r¼ 0.496 for BMD and Tb.Th, and r¼ 0.435 for BV/
TV and Tb.Th; all P < 0.050). Of note, the thickness of the calciﬁed
cartilage layer positively correlated with both, parameters of the
subarticular spongiosa (e.g., BV/TV: r ¼ 0.687; P ¼ 0.010) and the
total histological score for articular cartilage degeneration
(r ¼ 0.555; P ¼ 0.049). Most importantly, the correlation analysis
revealed that such early osteoarthritic changes of the articular
cartilage were ascribed to the increased thickness of the calciﬁed
cartilage layer (P ¼ 0.026) and the enhanced mineral density of the
subarticular spongiosa (P ¼ 0.001). Changes in BV/TV (P ¼ 0.234)
and Tb.Th (P ¼ 0.304) of the subarticular spongiosa did not
signiﬁcantly affect cartilage degeneration.
Discussion
To our best knowledge, this is the ﬁrst study to demonstrate that
systemic administration of PTH [1-34] leads to early osteoarthriticdegeneration of the articular cartilage, induced by altered struc-
tural parameters of the subchondral bone. Speciﬁcally, volume,
mineral density, and microarchitecture of the subarticular spon-
giosa were enhanced and the calciﬁed cartilage layer was broad-
ened following application of PTH [1-34] in vivo. Most importantly,
the correlation analysis revealed that such alterations of these
calciﬁed tissues accounted for the subsequently impaired structure
and reduced matrix staining of the hyaline articular cartilage.
PTH [1-34], the 1-34 amino acid segment of the full-length 84
amino acid PTH molecule9, is involved in the regulation of calcium
homeostasis16, increasing BMD10, cortical24 and trabecular thick-
ness, number and connectivity25, and bone strength, resulting in a
reduced fracture risk in animal models26 and patients10. Although
the majority of data for PTH [1-34] were collected for metaphyseal
bone healing or spinal fusion9, few investigations have also
assessed its effect on the subchondral bone. Recently, we have
demonstrated in an identical animal model that systemic PTH
[1-34] exerts its effects on both, the subchondral bone plate and the
subarticular spongiosa in knee focal osteochondral defects16. Thus,
similar to mechanisms occurring during the resolution of joint
inﬂammation27, PTH [1-34] generates an anabolic microenviron-
ment that supports bone formation and -according to our previous
data on serum calcium and alkaline phosphatase levels16- bone
remodeling processes. Interestingly, PTH [1-34] most likely yielded
these effects via systemic alterations of bone metabolism, as
neither cell numbers nor PTH1R expressionwithin the subchondral
bone were affected.
For focal chondral15 or osteochondral defects16 as well as
generalized osteoarthritic degeneration13, PTH [1-34] potently
enhanced articular cartilage repair. Interestingly, Bellido and co-
workers14 have demonstrated that an enhanced subchondral bone
support may reduce the progression of cartilage damage in exper-
imental osteoarthritis preceded by osteoporosis, underlining the
intimate cross-talk between articular cartilage and subchondral
bone2,28. The present investigation is the ﬁrst to extend our
knowledge of the effect of PTH [1-34] on the naïve osteochondral
unit -with no cartilage deterioration established therein. In this
regard, we report that PTH [1-34] had no beneﬁcial effect on
normal hyaline articular cartilage. Rather, its systemic administra-
tion induced early osteoarthritic changes2,29 such as a loss of
staining in the upper two thirds of the hyaline cartilage and
concomitant surface irregularities21 [Fig. 5]. Moreover, the corre-
lation analysis revealed that increased subchondral BMD and
enhanced thickness of the calciﬁed cartilage layer are the cause of
cartilage degeneration. The calciﬁed cartilage represents a transi-
tional zone of intermediate stiffness and plays a key role in trans-
ferring load to the subchondral bone30. Its broadening shares
similarities with the physiological process of endochondral bone
formation31,32. To date, these remodeling processes of the osteo-
chondral unit have been described mainly for late stage osteoar-
thritis31,33,34 and following joint overloading35. Most remarkably,
the importance of trabecular morphometry for articular cartilage
degeneration has recently been conﬁrmed in clinical trials36,37. The
data presented here indicate that such alterations are also crucially
involved in the very onset of the disease [Fig. 5] and that PTH [1-34]
could serve as a valuable model system to further investigate the
mechanisms involved in early osteoarthritis.
In the present investigation, broadening of the calciﬁed cartilage
layer under treatment with PTH [1-34] was not reﬂected in an
increased type-X collagen content of the cartilage compartment,
although type-X collagen deposition and matrix mineralization are
known to advance in parallel38. This may be explained by the
relatively early time point of investigation, impeding the visuali-
zation of increased type-X collagen contents subsequent to altered
gene expression proﬁles of osteoarthritic chrondrocytes29,39. Also,
Fig. 5. Schematic drawing displaying a synopsis of early osteoarthritic changes within the osteochondral unit induced by systemic treatment with PTH [1-34]. Systemic treatment
with PTH [1-34] induces an increase in BMD, BV/TV, Tb.Th and Tb.N within the subarticular spongiosa; the subchondral bone plate remains unaffected. Within the articular cartilage
compartment, the thickness of the calciﬁed cartilage layer is increased by PTH [1-34]. Of note, the thickness of the (non-calciﬁed) hyaline articular cartilage remains unaffected.
Therefore, the ratio of calciﬁed cartilage to hyaline articular cartilage is also increased [Fig. 2]. Moreover, PTH [1-34] treatment induces structural changes within the hyaline
cartilage layer reﬂective of early osteoarthritis, mainly a reduced safranin O staining intensity in the upper two thirds (reﬂective of a reduced proteoglycan content) together with
surface irregularities. These overall early osteoarthritic changes signiﬁcantly correlate with and are ascribed to the enhanced thickness of the calciﬁed cartilage layer and the
increased BMD of the subarticular spongiosa. Interestingly, no tidemark duplication and thickening (as described for late stage osteoarthritis)42 or thinning of the subchondral bone
plate (as described for early osteoarthritis)6 were noted at this early time point. Note that distances in the drawing may not be to scale.
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collagen contents. Possible explanations include the limitation of
these alterations to the superﬁcial articular cartilage, the lack of
chondrocyte apoptosis under PTH [1-34] treatment, and the early
time point of investigation (as type-II collagen loss is more a feature
of late stage osteoarthritis)29. Future molecular biological and
biochemical analyses will identify the time course of changes in
extracellular matrix composition. Yet, the ﬁndings that PTH [1-34]
did neither affect type-I and type-X collagen contents of the sub-
chondral bone nor type-II and type-X collagen within of the artic-
ular cartilage are in line with the study of Chang et al.13, reporting
that PTH [1-34] does not alter the proteoglycan and collagen
expression of normal chondrocytes. Therefore, although systemic
treatment with PTH [1-34] may have a beneﬁcial effect on injured
articular cartilage, a possible deterioration of the naïve hyaline
cartilage has to be born in mind.
The dosage of PTH [1-34] varies considerably among experi-
mental investigations26. While the same dose improved meta-
physeal bone healing of rabbits40, higher dosages (40 mg/kg/day
over 20 weeks) may cause renal failure41. The data on creatinine,
phosphate, and urea nitrogen demonstrate that no such systemic
side effect developed in our investigation following administration
of 10 mg PTH [1-34]/kg BW/day. Besides, the treatment did not in-
crease the apoptosis rate of cells within the osteochondral unit. Of
note, our previously published data applying the same rabbits16
indicate that treatment with PTH [1-34] over 42 days increased
serum levels of calcium (4.10 mmol/l) and alkaline phosphatase
(90.25 U/l) slightly but signiﬁcantly, conﬁrming the (patho-)
physiological effect of this treatment and validating the applied
animal model. However, as normal serum calcium levels in rabbits
range from 2.52 to 3.94 mmol/l41, no serious hypercalcemia (indi-
cating excessive bone resorption) was provoked by the treatment,
in linewith the fact that once daily injections of 20 mg PTH [1-34] do
not cause hypercalcemia in patients10.
Although the present model serves to dissect events associated
with the onset of early osteoarthritis6,42 in a clinically relevant large
joint [Fig. 5], a limitation of this study is the observation period of 6
weeks which does not allow to evaluate mid-term or late osteo-
arthritic changes. According to the Osteoarthritis Research Society
International (OARSI) histopathology initiative21, ﬁssures and
erosion of articular cartilage may occur as early as 4 weeks and full
depth erosions approximately 8 weeks following transection of the
anterior cruciate ligament43 in rabbits44. Additionally, although
sufﬁcient to detect signiﬁcant differences between groups, thenumber of experimental animals applied here was relatively small
and the clinical transferability of data obtained from quadruped
small animal models is limited. Future studies applying a higher
number of large animals and prolonged observation periods will
better translate to patients and further our understanding of the
role of endocrine factors in osteoarthritis. In this regard, the anal-
ysis of several joints within the same animal might yield a more
comprehensive understanding of PTH-induced effects upon the
musculoskeletal system. Also, the obtained results could have been
inﬂuenced by ﬂuctuations in hormone levels in female rabbits, fa-
voring males for future investigations. Besides, endogenous PTH
levels were not evaluated here but would be of interest for the
validation of this animal model, the exclusion of inter-individual
differences, and a comparison with endocrinological disorders
such as (pseudo-) hyperparathyroidism. A strength of the study is
the separate assessment of the subchondral bone plate and sub-
articular spongiosa and the use of a variety of robust methods to
analyze the articular cartilage. This enabled us to determine cor-
relations between PTH-induced changes in several key parameters
of the subchondral bone and the articular cartilage.
In conclusion, systemic administration of PTH [1-34] stimulates
volume, mineral density and microarchitecture of the subarticular
spongiosa in a normal lapine osteochondral unit. However, this
treatment also enhances the thickness of the calciﬁed cartilage
layer and provokes osteoarthritic cartilage degeneration. These
previously unrecognized effects of PTH [1-34] identify a potential
mechanism by which alterations of the normal subchondral bone
microarchitecture lead to a pattern of cartilage degeneration
consistent with features of early osteoarthritis already after 6
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